Wire · opportunities
Neuroendocrine Tumor Patients Gain a Second Lutetium Dotatate Option as FDA Approves ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
The FDA approved Curium's Bexlutry as a second lutetium Lu 177 dotatate radioligand treatment for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, adding a new manufacturer option alongside Lutathera. This approval via the 505(b)(2) pathway provides supply resilience for a time-sensitive cancer therapy with established clinical evidence but no new efficacy data.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 15 Sep 2026 and 18 Sep 2026.
◆ ◆ The Wire takeaway
You now face a choice of two FDA-approved lutetium radioligands for neuroendocrine tumors, easing supply risks tied to strict treatment timing. This opens room to negotiate pricing or supply terms and plan patient care with less chance of disruption.
◆ Coverage
3 sources · first reported 15 Sep 2026 · latest 18 Sep 2026
◆ Related on Wire
◆ Topics